Investor Hub

Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.

Latest investor presentation

Latest investor presentation

Latest clinical presentation
Latest quarterly earnings
Annual report

Annual report

Latest publications, posters & presentations

Our research

Global ticker
NASDAQNVAX
Latest press releases Events & presentation Reports & financials SEC filings Stock details & analyst coverage

SEC

Access filings by selecting the date range and type using the drop-down menus.

NASDAQNVAX
YearTrailing 12-monthsCalendar year 2023Calendar year 2022Calendar year 2021Calendar year 2020Calendar year 2019Calendar year 2018Calendar year 2017Calendar year 2016Calendar year 2015Calendar year 2014Calendar year 2013Calendar year 2012Calendar year 2011Calendar year 2010Calendar year 2009Calendar year 2008Calendar year 2007Calendar year 2006Calendar year 2005Calendar year 2004Calendar year 2003Calendar year 2002Calendar year 2001Calendar year 2000Calendar year 1999Calendar year 1998Calendar year 1997Calendar year 1996
TypeAll filingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
10-QQuarterly report which provides a continuing view of a company's financial positionNov 14, 1997Open Quarterly report which provides a continuing view of a company's financial position in HTML.Open Quarterly report which provides a continuing view of a company's financial position in DOC file.Open Quarterly report which provides a continuing view of a company's financial position in PDF file.Open Quarterly report which provides a continuing view of a company's financial position in XLS file.
10-QQuarterly report which provides a continuing view of a company's financial positionAug 12, 1997Open Quarterly report which provides a continuing view of a company's financial position in HTML.Open Quarterly report which provides a continuing view of a company's financial position in DOC file.Open Quarterly report which provides a continuing view of a company's financial position in PDF file.Open Quarterly report which provides a continuing view of a company's financial position in XLS file.
10-QQuarterly report which provides a continuing view of a company's financial positionMay 9, 1997Open Quarterly report which provides a continuing view of a company's financial position in HTML.Open Quarterly report which provides a continuing view of a company's financial position in DOC file.Open Quarterly report which provides a continuing view of a company's financial position in PDF file.Open Quarterly report which provides a continuing view of a company's financial position in XLS file.
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsApr 30, 1997Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 1, 1997Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.
SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%Mar 26, 1997Open Filing by person(s) reporting owned shares of common stock in a public company >5% in HTML.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in DOC file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in PDF file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in XLS file.
10-KAnnual report which provides a comprehensive overview of the company for the past yearMar 21, 1997Open Annual report which provides a comprehensive overview of the company for the past year in HTML.Open Annual report which provides a comprehensive overview of the company for the past year in DOC file.Open Annual report which provides a comprehensive overview of the company for the past year in PDF file.Open Annual report which provides a comprehensive overview of the company for the past year in XLS file.
SC 13G/AAmendment to a previously filed SC 13GMar 13, 1997Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
S-3Simplified registration formMar 4, 1997Open Simplified registration form in HTML.Open Simplified registration form in DOC file.Open Simplified registration form in PDF file.Open Simplified registration form in XLS file.
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Learn more

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.